Vanda Pharmaceuticals Inc.
VNDA
$4.92
-$0.10-1.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -413.78% | -512.58% | -805.05% | -853.29% | -239.24% |
| Total Depreciation and Amortization | 9.70% | 33.91% | 72.90% | 170.17% | 190.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -181.54% | -809.38% | -199.26% | -80.46% | -125.00% |
| Change in Net Operating Assets | 234.65% | 381.37% | 2.27% | -777.91% | 9.36% |
| Cash from Operations | -363.12% | -1,160.40% | -393.95% | -223.09% | -168.10% |
| Capital Expenditure | 98.95% | 98.95% | 97.64% | 95.33% | -26,725.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.00% | -27.72% | 141.40% | -114.28% | -62.61% |
| Cash from Investing | 182.79% | 206.55% | 120.54% | -44.58% | -160.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -205.29% | 5,000.00% | -733.33% | -446.81% | 136.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.15% | 53.33% | 94.17% | -4,330.43% | -161.81% |